Objective:To observe the role of Zhike Qingfei Oral Liquid in treatment of the airway inflammation of chronic obstructive pulmonary diseases（COPD）.Methods:50 cases with COPD at stable stage were divided into a treatment group and a control group

25 cases in each.Patients in both groups were treated with conventional therapy

including oxygen therapy

cardiactonic diuresis and relieving cough and asthma

etc.Zhike Qingfei Oral Liquid was added to the patients

of the treatment group

20ml each time

3 times each day

for 6 weeks.Clinical scores

pulmonary function

cell count and classification

interleukin-8（IL-8）and tumor necrosis Factor-α（TNF-α）in the sputum before and after treatment were investigated.Results:In the treatment group.the clinical score

FEV

1

and FEV

1

/FVC（%）improved significantly（P

<

0.05 or P

<

0.01）after treatment

and no significant change was found in the control group.Total number of cells

neutrophil percentage

level of IL-8 and TNF-α in the sputum were significantly declined

but no significant change was found in the control group.Conclusion:Zhike Qingfei Oral Liquid has obvious therapeutic effect on airway inflammation of COPD.